Fenotipo de la haptoglobina y presencia de enfermedad vascular subclínicaestudio poblacional

  1. Mostaza, Jose M. 1
  2. de Dios, Olaya 2
  3. Lahoz, Carlos
  4. Arribas, Marta 1
  5. Pérez Arroyo, Alicia 2
  6. Salinero-Fort, Miguel A. 3
  7. Laguna, Fernando
  8. Estirado, Eva
  9. García-Iglesias, Francisca
  10. González Alegre, Teresa
  11. Sabín, Concesa
  12. López, Silvia
  13. Sánchez, Vanesa 4
  14. Cornejo, Víctor
  15. Garcés, Carmen
  1. 1 Unidad de Lípidos y Riesgo Cardiovascular, Servicio de Medicina Interna, Hospital Carlos III, Madrid, España
  2. 2 Laboratorio de Lípidos, IIS-Fundación Jiménez Díaz, UAM, Madrid, España
  3. 3 Gerencia Adjunta de Planificación y Calidad Atención Primaria, Servicio Madrileño de Salud, Madrid, España
  4. 4 Unidad de día, Hospital Carlos III, Madrid, España
Show affiliations +
Journal:
Clínica e investigación en arteriosclerosis

ISSN: 0214-9168,  1578-1879

Year of publication: 2020

Volume: 32

Issue: 1

Pages: 1-7

Type: Article

DOI: HTTPS://DOI.ORG/10.1016/J.ARTERI.2019.03.007 DIALNET GOOGLE SCHOLAR

More publications in: Clínica e investigación en arteriosclerosis

Abstract

Introduction and objectives Haptoglobin is a protein involved in the protection against oxidative damage caused by iron in haemoglobin. This protein is polymorphic, with 3 isomorphs prevalent in the population. The carriers of the Hp2-2 isoform have a lower antioxidant capacity and, in the population with diabetes, an increased risk of subclinical vascular disease and cardiovascular complications. The objective of this study was to evaluate whether this isomorphy is associated with an increased risk of carotid arteriosclerosis in subjects with and without diabetes, and free of cardiovascular disease. Patients and methods A study was conducted in a population between 45 and 74 years of age, randomly selected from the northwest area of Madrid. The participants were characterised in terms of their glycaemic status by oral glucose overload and the determination of the concentration of Hb1Ac. The haptoglobin phenotypes in all of them were determined by means of an immunoenzymatic assay, and the presence of carotid arteriosclerosis by ultrasound. Results Of the 1,256 participants included in the present analysis (mean age 61.6 ± 6 years, 41.8% males), the distribution of the isoforms of haptoglobin was as follows: Hp1-1: 13.3%, Hp1-2: 48.5%, and Hp2-2: 38.2%. In comparison with subjects Hp1-1 and Hp1-2, those with the Hp2-2 phenotype had a higher prevalence of dyslipidaemia (53.3% vs 43%; P < .0001) and arterial hypertension (39.2% vs. 32.2%, P = .012), and they more frequently received treatment with statins (31.5% vs 21.6%, P < .0001), and with antihypertensive agents (38.4% vs 30.8%, P = .006). The carriers of the Hp2-2 isoform had a higher prevalence of carotid plaques (OR: 1.35, 95% CI: 1.07-1.69, P = .011), with no differences in that prevalence as regards the glycaemic status. There were no differences in the intima-media thickness between the different phenotypes. The relationship of the Hp2-2 phenotype with the presence of plaques in the carotid was independent of age, gender, presence of risk factors (dyslipidaemia, hypertension and diabetes), the concentration of LDL-cholesterol, C-reactive protein and uric acid, blood pressure, and treatment with statins, and hypertensive drugs (OR: 1.31, 95% CI 1.01-1.70, P = .044). Conclusion Subjects with the Hp2-2 phenotype of haptoglobin have a higher prevalence of carotid arteriosclerosis, which is independent of the presence of other cardiovascular risk factors and their glycaemic status.

Data source: Dialnet